fda nasal spray depression

FDA-Approved Nasal Spray For Depression Is 1st Of Its Kind

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Popular Science · 3d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Medscape · 1d

FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.

FDA approves Spravato as first stand-along nasal spray to treat drug-resistant depression

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

FDA-Approved Nasal Spray For Depression Is 1st Of Its Kind

Trending now